Fly News Breaks for March 2, 2015
SCMP
Mar 2, 2015 | 06:14 EDT
Credit Suisse downgraded Sucampo (SCMP) to Underperform based on valuation, and increased concerns regarding long-term competitive threats to the base business from Ironwood Pharmaceutical's (IRWD) Linzess, which has a superior efficacy and clinical profile. Price target raised to $13 from $10.
News For SCMP From the Last 2 Days
There are no results for your query SCMP